Study Links Wegovy to Higher Reported Risk of Rare Eye Condition
Similar Articles
GLP-1 Medications Linked to Reduced Psychiatric Hospitalizations and Sick Leave
Semaglutide Shows Significant Weight Loss Benefits for Older Adults with Obesity
Significant Weight Loss from GLP-1 Drugs Linked to Lower Risk of Chronic Conditions
Study Finds Weight Loss via GLP-1 Medications Attracts More Stigma Than Diet and Exercise
GLP-1 Receptor Agonists Reduce Cardiovascular Risk Across Patient Groups
A new analysis of U.S. safety reports suggests the weight-loss drug Wegovy may be associated with a higher reported risk of a rare condition that can cause sudden vision loss, compared to other semaglutide medications. The study, based on a database of over 30 million adverse event reports, found a stronger statistical signal for Wegovy than for the diabetes drug Ozempic. Researchers emphasize the findings show an association, not proven causation, and note that GLP-1 drugs also have potential benefits for other eye and health conditions.
Facts First
- Wegovy showed a stronger statistical signal for ischemic optic neuropathy (ION) than Ozempic or generic semaglutide in an analysis of FDA adverse event reports.
- ION is a rare condition that can cause sudden partial or complete blindness due to reduced blood flow to the optic nerve.
- The analysis reviewed over 30.6 million reports submitted to the FDA Adverse Event Reporting System (FAERS) between 2017 and 2024.
- Men using Wegovy showed the highest signal for ION, with odds 116 times higher than expected in the database.
- GLP-1 drugs like semaglutide may also benefit other eye conditions and reduce risks linked to cardiovascular disease and stroke, according to the research.
What Happened
Researchers analyzed reports from the U.S. Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) submitted between December 2017 and December 2024. The database analysis included more than 30.6 million adverse event reports, of which 31,774 involved semaglutide drugs. The analysis included the injectable diabetes drug Ozempic, the injectable weight-loss drug Wegovy, the oral semaglutide tablet Rybelsus, and tirzepatide drugs including Mounjaro and Zepbound. Wegovy showed 28 reports of ischemic optic neuropathy (ION), while Ozempic showed 47 reports. The statistical signal for Wegovy showed odds nearly 75 times higher than expected, compared to odds of nearly 19 for Ozempic and odds of 21 for generic semaglutide products. No cases of ION were reported for Rybelsus.
Why this Matters to You
If you or someone you know is taking a GLP-1 medication like Wegovy or Ozempic, this study highlights a rare but serious potential side effect to be aware of. Ischemic optic neuropathy (ION) can cause sudden partial or complete blindness in one or both eyes. The risk appears to be very low, given the small number of reports among millions of users, but the statistical signal suggests it may be worth discussing with your doctor, especially if you are a man using Wegovy, as that group showed the highest signal. It is important to remember that these drugs also have significant benefits; research suggests they may help reduce risks linked to cardiovascular disease, stroke, and dementia, and may benefit certain other eye conditions.
What's Next
The study authors have identified a statistical association that warrants further investigation. Future research will likely be needed to determine if there is a direct causal link between Wegovy and ION. In the meantime, patients using these medications may want to monitor for any sudden vision changes and report them to their healthcare provider. Regulatory bodies like the FDA may review this data as part of their ongoing safety monitoring for this widely used class of drugs.